The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers and overall survival rates have barely improved over the past five decades. The antimetabolite gemcitabine remains part of the standard-of-care, but shows very limited anti-tumor efficacy. Ataxia telangiectasia and Rad3-related p...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mol Cancer Ther
Glavni autori: Wallez, Yann, Dunlop, Charles R, Johnson, Timothy Isaac, Koh, Siang-Boon, Fornari, Chiara, Yates, James WT, Bernaldo de Quirós Fernández, Sandra, Lau, Alan, Richards, Frances M, Jodrell, Duncan I
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6076438/
https://ncbi.nlm.nih.gov/pubmed/29891488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0010
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items